References
- 1. Berg K. A new serum type system in man: the Lipoprotein(a) system. Acta Pathol Microbiol Scand. 1963;59:369-382.
- 2. Watts GF, Keamey EM, Taub NA, Slavin BM. Lipoprotein(a) as an independent risk factor for myocardial infarction in patients with common hypercholesterolaemia. Jf Clin Patho. 1993;46:267-270.
- 3. Zhu X, Cheng SY. New insights into regulation of lipid metabolism by thyroid hormone. Current Opinion in Endocrinology, Diabetes and Obesity. 2010;17(5):408-413.
- 4. Fruchart JC, Nierman MC, Stroes ES, Kastelein JJ, Duriez P. New risk factors for atherosclerosis and patient risk assessment. Circulation. 2004;109III:15-19.
- 5. Discepolo W, Wun T, Berglund L. Lipoprotein(a) and thrombocytes: potential mechanisms underlying cardiovascular risk. Pathophysiol Haemost Thromb. 2006;35:314-21.
- 6. Koschinsky ML. Novel insights into Lp(a) physiology and pathogenicity: more questions than answers? Cardiovasc Hematol Disord Drug Targets. 2006;6:267-78.
- 7. Anuurad E, Boffa MB, Koschinsky ML, Berglund L. Lipoprotein(a): a unique risk factor for cardiovascular disease. Clin Lab Med. 2006;26:751-72.
- 8. Zorio E, Falco C, Arnau MA, et al. Lipoprotein(a) in young individuals as a marker of the presence of ischemic heart disease and the severity of coronary lesions. Haematologica. 2006;91:562-5.
- 9. Santi A, Duarte M, Moresco RN, et al. Association between thyroid hormones, lipids and oxidative stress biomarkers in overt hypothyroidism. Clinical Chemistry and Laboratory Medicine. 2010;48(11):1635-1639.
- 10. Roos A, Bakker SJ, Links TP, Gans RO, Wolffenbuttel BH. Thyroid function is associated with components of the metabolic syndrome in euthyroid subjects. J Clin Endocrinol Metab. 2007;92:491-6.
- 11. Peppa M, Betsi G, Dimitriadis G. Lipid Abnormalities and Cardiometabolic Risk in Patients with Overt and Subclinical Thyroid Disease. J Lipids. 2011; 2011: 575840. Published online 2011 July 18. doi: 10.1155/2011/575840.
- 12. Asvold BO, Vatten LJ, Nilsen TI, Bjoro T. The association between TSH within the reference range and serum lipid concentrations in a populationbased study. The HUNT Study. Eur J Endocrinol. 2007;156:181-6.
- 13. Enkhmaa B, Anuurad E, Zhang W, Tran T, Berglund L. Lipoprotein(a): genotype-phenotype relationship and impact on atherogenic risk. Metab Syndr Relat Disord. 2011;9(6):411-8.
- 14. Bruckert E, Thomas D. Les hypercholesterolemies. John Libbey Eurotext, London, 1997, 28-53.
- 15. Takagi H. Atorvastatin decreases lipoprotein(a): a meta-analysis of randomized trials. Int J Cardiol. 2012;154(2):183-6.
- 16. Dumitrescu L, Glenn K, Brown-Gentry K et al. Variation in LPA is associated with Lp(a) levels in three populations from the Third National Health and Nutrition Examination Survey. 2011 PLoS ONE 6 (1): e16604.
- 17. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 2010;31(23):2844-53.
- 18. Dubé JB, Boffa MB, Hegele RA, Koschinsky ML. Lipoprotein(a): more interesting than ever after 50 years. Curr Opin Lipidol. 2012;23(2):133-40.
- 19. George RM, Torelli J. Beyond cholesterol: 7 life-saving heart disease tests that your doctor may not give you. New York: St. Martin's Griffin. 2005. p.91.
- 20. De Bruin TW, van Barlingen H, van Linde-Sibenius TM, et al. Lipoprotein(a) and Apolipoprotein B plasma concentrations in hypothyroid, euthyroid and hyperthyroid subjects. J Clin Endocrinol Metab. 1993;76:121-126.
- 21. Rizos CV, Elisaf MS, Liberopoulos EN. Effects of Thyroid Dysfunction on Lipid Profile. Open Cardiovasc Med J. 2011;5:76-84.
- 22. Boda J, Paragh G, Szabo J, et al. Lipoprotein(a) studies in thyroid diseases. Orv Hetil. 1997;138:2307.
- 23. Lotz H, Salabe GB. Lipoprotein(a) increase associated with thyroid autoimmunity. Eur J Endocrinol. 1997;136(1):87-91.
- 24. Bairaktari ET, Tselepis AD, Millionis HJ, Elisaf MS. Lipoprotein(a) levels, apoLipoprotein(a) phenotypes and thyroid autoimmunity. Eur J Endocrinol. 1999;140:474-6.
- 25. Tagami T, Tamanaha T, Shimazu S, et al. Lipid profiles in the untreated patients with Hashimoto thyroiditis and the effects of thyroxine treatment on subclinical hypothyroidism with Hashimoto thyroiditis. Endocrine Journal. 2010;57(3):253-258.
- 26. Toruner F, Altinova AE, Karakoc A, et al. Risk factors for cardiovascular disease in patients with subclinical hypothyroidism. Adv Ther. 2008; 25:430-7.
- 27. Dullaart RPF, van Doormaal JJ, Hoogenberg K, Sluiter WJ. Triiodothyronine rapidly lowers plasma Lipoprotein(a) in hypothyroid subjects. Netherlands Journal of Medicine. 1995;46(4):179-184.
- 28. Lee WY, Suh JY, Rhee EJ, et al. Plasma CRP, apolipoprotein A-1, apolipoprotein B and Lp(a) levels according to thyroid function status. Arch Med Res. 2004;35:540-5.
- 29. Lippi G, Targher G, Montagnana M, Salvagno GL, Guidi GC. Relationship between Lipoprotein(a) and thyroid function status in the general population. Arch Med Res. 2007;38:905-6.
- 30. Riche DM, East HE, Priest HM. Practical management of dyslipidemia with elevated Lipoprotein(a). J Am Pharm Assoc. 2008;48(6):803-7.
- 31. Neves C, Alves M, Medina JL, Delgado JL. Review Thyroid diseases, dyslipidemia and cardiovascular pathology. Rev Port Cardiol. 2008; 27(10):1211-36.
- 32. Teixeira P, Reuters VS, Ferreira MM, et al. Lipid profile in different degrees of hypothyroidism and effects of levothyroxine replacement in mild thyroid failure. Translational Research. 2008;151(4):224-231.